PUBLISHER: Inkwood Research | PRODUCT CODE: 1142631
PUBLISHER: Inkwood Research | PRODUCT CODE: 1142631
The India epilepsy devices market is expected to propel with a 9.63% CAGR between the assessment years 2022 and 2028. The market growth is driven by prevalent traffic accidents, infections, and growing awareness among the citizens.
Infections continue to be a major cause and concern for policymakers in India despite great improvements in the nation's prevention and management of communicable and infectious illnesses. Further, socioeconomic factors influence the risk of epilepsy and its prognosis because of its high correlation with birth trauma, infections, poor nutrition, poor cleanliness, and poor health-seeking behavior. Risk factors for secondary seizures include disorders like brain damage and hypoxia brought on by subpar delivery care, maternal malnutrition, infection during pregnancy, traumatic/acquired brain injuries, and specific metabolic abnormalities.
One of the main causes of epilepsy in India is traffic accidents. Even if such epilepsy episodes might be avoided, the general public is not well informed. The prevalence of childhood epilepsy is rising. With the introduction of new investigations and technology, it is being identified more frequently, and as public awareness has grown, cases are being detected more easily.
Some leading players operating in the market include: Shenzhen Mindray Bio-Medical Electronics Co Ltd, Nihon Kohden Corporation, Koninklijke Philips NV, etc.